Table 3.

The association of CYP1B1 and COMT genotypes with ER/PR status among breast cancer cases, the Shanghai Breast Cancer Study

ER−/ER+*OR (95% CI)PPR−/PR+*OR (95% CI)P
CYP1B1
    Codon 48
        Arg/Arg163/3301.00 (reference)169/3181.00 (reference)
    Other101/1450.71 (0.52-0.97)0.03390/1540.91 (0.66-1.25)0.561
    Codon 119
        Ala/Ala160/3321.00 (reference)165/3211.00 (reference)
    Other104/1440.67 (0.49-0.91)0.01292/1540.86 (0.63-1.18)0.356
    Codon 432
        Leu/Leu205/3471.00 (reference)194/3521.00 (reference)
    Other60/1211.19 (0.84-1.70)0.33364/1150.99 (0.70-1.41)0.957
COMT
    Val/Val149/2461.00 (reference)145/2451.00 (reference)
    Other114/2311.23 (0.91-1.66)0.185113/2291.20 (0.88-1.63)0.242
  • * The number of patients with ER−/ER+ or PR−/PR+.

  • The ORs (95% CIs) estimating the probability of ER+ or PR+.

  • Combining the other two genotypes for each single nucleotide polymorphism.